{
    "nctId": "NCT03183206",
    "briefTitle": "Safety and Efficiency of \u03b3\u03b4 T Cell Against Breast Cancer",
    "officialTitle": "\u03b3\u03b4 T Cell Immunotherapy for Treatment of Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Relief degree of tumors",
    "eligibilityCriteria": "Inclusion Criteria:\n\nAge: 18-75 Karnofsky performance status \\>50 Diagnosis with Breast Cancer based on histology or the current accepted radiological measures Classification tumor,nodes,metastasis-classification(TNM) stage: \u2161,\u2162,\u2163 Will receive cryosurgery, IRE, surgery, gd T cells Life expectancy: Greater than 6 months Ability to understand the study protocol and a willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPatients with other kinds of cancer History of coagulation disorders or anemia Patients with heart disease Insulin dependent diabetes Thyroid disease",
    "sex": "FEMALE",
    "minimumAge": "15 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}